Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICLE 2022 | T-cell engineering advances at ICLE 2022

Michael Traxlmayr • 1 Apr 2022
ICLE 2022
General CAR-T

Michael Traxlmayr, PhD, University of Natural Resources and Life Sciences, Vienna, Austria, gives his highlights within the burgeoning field of immune cell engineering presented at the International Conference on Lymphocyte Engineering (ICLE) 2022. Notable advances include developing cellular therapies based on Foxp3+ regulatory T (Treg) cells, which will potentially represent the next generation of T-cell therapies. This interview took place at ICLE 2022.

More from Michael Traxlmayr

1:02
Expanding the clinical applications of AvidCAR T-cells
Michael Traxlmayr • 1 Apr 2022
0:43
Developing an AvidCAR platform to improve T-cell activity
Michael Traxlmayr • 1 Apr 2022

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals